People in the study who recently took up crossword puzzles didn’t see added benefit. ‘What our data suggests is usually that a whole lifetime of engaging in these activities has a bigger impact than being cognitively energetic just in older age,’ Landau MyHealthNewsDaily told. Around 5.4 million People in america live with Alzheimer’s disease. Alzheimer’s disease is the sixth leading reason behind death in the U.S., according to the CDC’s latest record, taking a lot more than 83,000 lives this past year.S. Food and Medication Administration . Related StoriesImmune submits Bertilimumab IND application to FDA for treatment of Bullous PemphigoidMylan sued regarding the ANDA filing for generic version of ZytigaTARSA Therapeutics' TBRIA NDA approved by FDA for reviewCelgene intends to vigorously enforce its comprehensive intellectual property privileges for REVLIMID and plans to file a complaint alleging infringement within the mandatory 45-time response period.The Company is currently evaluating various delivery technology to clinically deliver MANF to the brain in Parkinson's disease, and can update the market of its intentions seeing that definitive agreements emerge.’ Large pharmaceutical companies have shown significant interest in neurotrophic factors for Parkinson's disease for over 2 decades. In 1993, Amgen obtained Synergen for $262 million shortly after Synergen effectively completed studies using GDNF as a proteins therapeutic in animal models of Parkinson's disease. In 2007, Genzyme entered right into a $150 million partnership with Ceregene to gain usage of ex-U.S.